[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
OBJECTIVE
Statins are frequently given in conjunction with clopidogrel for prophylaxis and therapy of coronary heart disease. The antiplatelet effect of clopidogrel may be attenuated by lipophilic statins such as atorvastatin. It was the aim of this study to measure the antiplatelet effect of clopidogrel and the incidence of cardiovascular events after stent implantation in patients with coronary artery stenting.


METHODS
ADP-induced aggregometry was used in 319 patients after coronary artery stent implantation to determine whether added administration of clinically relevant statins would affect the antiplatelet action of clopidogrel. Also a three-month follow-up was undertaken to determine the incidence of cardiovascular events.


RESULTS
There were no significant differences between the statin-receiving subgroups, either in platelet aggregation nor in clinical outcome in our cohort.


CONCLUSIONS
No statin-clopidogrel interaction nor any clinically relevant events were documented in the studied cohort. No interaction between CYP3A4 statins and a single loading dose of 600 mg clopidogrel was documented in this cohort.
Zürn
C S
CS
Medizinische Klinik, Abteilung III, Universitätsklinikum Tübingen, Tübingen. christine.zuern@med.uni-tuebingen.de
Geisler
T
T
Paterok
M
M
Gawaz
M
M
D000069059:Atorvastatin; D000077144:Clopidogrel; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D023921:Coronary Stenosis / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D019821:Simvastatin / Q000627:therapeutic use; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000077340:Fluvastatin; D000069059:Atorvastatin; D000077144:Clopidogrel; D019821:Simvastatin; D013988:Ticlopidine